TherapeuticsMD, Inc. Stock

Equities

TXMD

US88338N2062

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
1.86 USD -0.53% Intraday chart for TherapeuticsMD, Inc. 0.00% -17.33%
Sales 2022 69.96M Sales 2023 1.3M Capitalization 25.77M
Net income 2022 112M Net income 2023 -10M EV / Sales 2022 0.34 x
Net cash position 2022 29.31M Net Debt 2023 3.68M EV / Sales 2023 22.6 x
P/E ratio 2022
0.47 x
P/E ratio 2023
-2.28 x
Employees 1
Yield 2022 *
-
Yield 2023
-
Free-Float 96.22%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.53%
Current month-18.78%
1 month-17.33%
3 months-18.06%
6 months-7.00%
Current year-17.33%
More quotes
1 week
1.86
Extreme 1.86
1.93
1 month
1.86
Extreme 1.86
2.38
Current year
1.86
Extreme 1.86
2.75
1 year
1.86
Extreme 1.86
4.73
3 years
1.86
Extreme 1.86
69.50
5 years
1.86
Extreme 1.86
234.50
10 years
1.86
Extreme 1.86
563.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 13-05-31
Director of Finance/CFO - 23-08-16
Corporate Officer/Principal - 18-02-28
Members of the board TitleAgeSince
Chairman 81 12-04-15
Director/Board Member 45 12-02-27
Director/Board Member 69 20-03-19
More insiders
Date Price Change Volume
24-04-26 1.86 -0.53% 6,236
24-04-25 1.87 -2.60% 10,593
24-04-24 1.92 +2.13% 14,863
24-04-23 1.88 0.00% 20,731
24-04-22 1.88 +1.08% 19,137

Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT

More quotes
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
More about the company